IMC Chicago’s Vertex Pharmaceuticals VRTX Stock Holding History

IMC Chicago’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.02M	Buy	+4,533	New	+$2.11M	﹤0.01%	2555

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

IMC Chicago's VRTX Position: Q1 2026 in Review

IMC Chicago opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 4,533 shares worth $2.02M. The stake represents ﹤0.01% of the portfolio and ranks #2555 among its holdings.

1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

IMC Chicago held 4,533 shares of Vertex Pharmaceuticals worth $2.02M as of Q1 2026.
Vertex Pharmaceuticals was a new IMC Chicago position in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #2555 holding.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.